CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of


Journal

Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410

Informations de publication

Date de publication:
05 2022
Historique:
received: 25 04 2021
revised: 05 08 2021
pubmed: 21 8 2021
medline: 4 5 2022
entrez: 20 8 2021
Statut: ppublish

Résumé

There is a need for in vivo diagnostic imaging probes that can noninvasively measure tumor-infiltrating CD8+ leukocytes. Such imaging probes could be used to predict early response to cancer immunotherapy, help select effective single or combination immunotherapies, and facilitate the development of new immunotherapies or immunotherapy combinations. This study was designed to optimize conditions for performing CD8 PET imaging with

Identifiants

pubmed: 34413145
pii: jnumed.121.262485
doi: 10.2967/jnumed.121.262485
pmc: PMC9051598
doi:

Substances chimiques

Zirconium C6V6S92N3C

Banques de données

ClinicalTrials.gov
['NCT03107663']

Types de publication

Clinical Trial, Phase I Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

720-726

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States

Informations de copyright

© 2022 by the Society of Nuclear Medicine and Molecular Imaging.

Références

J Immunother Cancer. 2019 Jan 30;7(1):23
pubmed: 30700328
Ann ICRP. 2007;37(2-4):1-332
pubmed: 18082557
PLoS One. 2010 Jan 25;5(1):e8859
pubmed: 20111600
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
J Nucl Med. 2019 Mar;60(3):335-341
pubmed: 30413661
Cancer Res. 2020 Jul 1;80(13):2903-2913
pubmed: 32409308
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
J Nucl Med. 2009 Nov;50(11):1828-36
pubmed: 19837762
Nat Med. 2019 Mar;25(3):454-461
pubmed: 30804515
Cell. 2018 Aug 9;174(4):1031-1032
pubmed: 30096300
J Nucl Med. 2018 Jun;59(6):900-906
pubmed: 29146695
J Nucl Med. 1999 Feb;40(2):37S-61S
pubmed: 10025848
N Engl J Med. 2012 Jun 28;366(26):2455-65
pubmed: 22658128
Br J Cancer. 2011 Jun 28;105(1):93-103
pubmed: 21629244
J Nucl Med. 2010 Aug;51(8):1293-300
pubmed: 20660376
J Immunother Cancer. 2020 Apr;8(1):
pubmed: 32345624
JAMA Netw Open. 2019 May 3;2(5):e192535
pubmed: 31050774
Nucl Med Biol. 2009 Oct;36(7):729-39
pubmed: 19720285
Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):95-101
pubmed: 28831583
J Nucl Med. 2005 Jun;46(6):1023-7
pubmed: 15937315
Clin Nucl Med. 2020 Apr;45(4):267-275
pubmed: 32108700
J Nucl Med. 2016 Dec;57(12):1858-1864
pubmed: 27516450
Eur J Nucl Med Mol Imaging. 2020 Nov;47(12):2776-2786
pubmed: 32338306
J Nucl Med. 2020 Apr;61(4):512-519
pubmed: 31586002
J Clin Oncol. 2012 Jul 20;30(21):2678-83
pubmed: 22711850
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
Am J Nucl Med Mol Imaging. 2017 Sep 01;7(4):195-203
pubmed: 28913158
J Nucl Med. 2017 Sep;58(9):1421-1428
pubmed: 28360208
Clin Nucl Med. 2019 Apr;44(4):e272-e279
pubmed: 30688730
Mol Imaging Biol. 2016 Dec;18(6):952-959
pubmed: 27146421

Auteurs

Michael D Farwell (MD)

Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; michael.farwell@pennmedicine.upenn.edu.
Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

Raymond F Gamache (RF)

Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

Hasan Babazada (H)

Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

Matthew D Hellmann (MD)

Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Medicine, Weill Cornell Medical College, New York, New York.

James J Harding (JJ)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Medicine, Weill Cornell Medical College, New York, New York.

Ron Korn (R)

Imaging Endpoints, Scottsdale, Arizona.

Alessandro Mascioni (A)

ImaginAb, Inc., Inglewood, California.

William Le (W)

ImaginAb, Inc., Inglewood, California.

Ian Wilson (I)

ImaginAb, Inc., Inglewood, California.

Michael S Gordon (MS)

HonorHealth Research Institute, Scottsdale, Arizona.

Anna M Wu (AM)

ImaginAb, Inc., Inglewood, California.
Department of Molecular Imaging and Therapy, Beckman Research Institute of the City of Hope, Duarte, California.

Gary A Ulaner (GA)

Molecular Imaging and Therapy, Hoag Family Cancer Institute, Newport Beach, California.

Jedd D Wolchok (JD)

Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Medicine, Weill Cornell Medical College, New York, New York.
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Michael A Postow (MA)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Medicine, Weill Cornell Medical College, New York, New York.

Neeta Pandit-Taskar (N)

Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York; and.
Department of Radiology, Weill Cornell Medical College, New York, New York.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH